A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Drug Metabolism And Disposition

• Publication date

  2001-03-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  PMID 11181496
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Atorvastatin Coadministration May Increase Digoxin Concentrations by Inhibition of Intestinal P‐Glycoprotein‐Mediated Secretion

  2000cited by this paper
• Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver.

  1998cited by this paper
• Effect of itraconazole on the pharmacokinetics of atorvastatin

  1998cited by this paper
• Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole

  1998cited by this paper
• Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P450 isozymes involved.

  1997cited by this paper
• Cooperativity in oxidations catalyzed by cytochrome P450 3A4.

  1997cited by this paper
• In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s.

  1997cited by this paper
• Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid

  1996cited by this paper
• In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors

  1996cited by this paper
• In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (±)‐fluvastatin

  1995cited by this paper
• Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole

  1994cited by this paper
• Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes.

  1991cited by this paper
• In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase.

  1990cited by this paper

• Sinomenine in Cardio-Cerebrovascular Diseases: Potential Therapeutic Effects and Pharmacological Evidences

  2021cites this paper
• Assessment of Statin Interactions With the Human NTCP Transporter Using a Novel Fluorescence Assay

  2020cites this paper
• The potential of Atorvastatin for chronic lung diseases therapy

  2020cites this paper
• Hepatic and intestinal biotransformation gene expression and drug disposition in a dextran sulfate sodium-induced colitis mouse model

  2019cites this paper
• In vitro/in silico approach in the development of simvastatin-loaded self-microemulsifying drug delivery systems

  2018cites this paper
• Co‐administration with simvastatin or lovastatin alters the pharmacokinetic profile of sinomenine in rats through cytochrome P450‐mediated pathways

  2018cites this paper
• Repurposing of statins via inhalation to treat lung inflammatory conditions

  2018cites this paper
• HPLC-MS analysis of Atorvastatin and its metabolites in plasma and prostate cancer tissue

  2017cites this paper
• SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid

  2015cites this paper
• Review article: inhibition of methanogenic archaea by statins as a targeted management strategy for constipation and related disorders

  2015cites this paper
• Development of In Vitro-In Vivo Correlation/Relationship Modeling Approaches for Immediate Release Formulations Using Compartmental Dynamic Dissolution Data from “Golem”: A Novel Apparatus

  2015cites this paper
• Studies of hepatic drug transport and metabolism in different model systems

  2014cites this paper
• Regulation of Intestinal Cytochrome P450 Expression by Hepatic Cytochrome P450: Possible Involvement of Fibroblast Growth Factor 15 and Impact on Systemic Drug Exposure

  2014cites this paper
• Statins and Neuroprotection: Basic Pharmacology Needed

  2014cites this paper
• Characterization of the Active Site Properties of CYP 4 F 12 s

  2014cites this paper
• Characterization of the Active Site Properties of CYP4F12

  2014cites this paper
• Determination of statins by gas chromatography - EI/MRM - Tandem mass spectrometry: fermentation of pine samples with Pleurotus ostreatus.

  2014cites this paper
• The Effects of Statin and Fibrate Drugs on Cholesterol Metabolism and Steroid Production in Two Fish Species

  2014cites this paper
• In vitro metabolism of tetrazole aminoquinolines and derivatives of metergoline and fusidic acid

  2014cites this paper
• DMD059626 1698..1707

  2014cites this paper
• ATP-dependent transport of statins by human and rat MRP2/Mrp2.

  2013cites this paper
• Model-Based Approaches to Characterize Clinical Pharmacokinetics of Atorvastatin and Rosuvastatin in Disease State

  2013cites this paper
• Hydrophobic statins induce autophagy and cell death in human rhabdomyosarcoma cells by depleting geranylgeranyl diphosphate.

  2012cites this paper
• Determination of Log P by Dispersive Liquid/Liquid Microextraction Coupled with Derivatized Magnetic Nanoparticles Predispersed in 1-Octanol Phase

  2012cites this paper
• Drug Interactions with Benzodiazepines: Epidemiologic Correlates with Other CNS Depressants and In Vitro Correlates with Inhibitors and Inducers of Cytochrome P450 3A4

  2012cites this paper
• Evaluation of Organic Anion-Transporting Polypeptide 1B1 and CYP3A4 Activities in Primary Human Hepatocytes and HepaRG Cells Cultured in a Dynamic Three-Dimensional Bioreactor System

  2012cites this paper
• The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance

  2012influential citation
• Blockbuster interactions: are they bad for the patient?

  2012cites this paper
• Simultaneous Assessment of Uptake and Metabolism in Rat Hepatocytes: A Comprehensive Mechanistic Model

  2012cites this paper
• Concomitant administration of simvastatin with ivabradine in contrast to metoprolol intensifies slowing of heart rate in normo- and hypercholesterolemic rats

  2012cites this paper
• Concomitant Administration of Different Doses of Simvastatin with Ivabradine Influence on PAI-1 and Heart Rate in Normo- and Hypercholesterolaemic Rats

  2012cites this paper
• Comparison of the effects of dietary flavonoids and statins on lipopolysaccharide-induced vascular inflammation

  2011cites this paper
• Role of Intestinal Cytochrome P450 (P450) in Modulating the Bioavailability of Oral Lovastatin: Insights from Studies on the Intestinal Epithelium-Specific P450 Reductase Knockout Mouse

  2011cites this paper
• Metabolic fate of pitavastatin (NK-104), a new inhibitor of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase. Effects on drug-metabolizing systems in rats and humans.

  2011cites this paper
• Frozen water phase method for logD measurement using a 96-well plate.

  2011cites this paper
• The statin class of HMG-CoA reductase inhibitors demonstrate differential activation of the nuclear receptors PXR, CAR and FXR, as well as their downstream target genes

  2011influential citation
• Physiologically Based Pharmacokinetic Modeling of Intestinal First-Pass Metabolism of CYP3A Substrates with High Intestinal Extraction

  2011cites this paper
• Enhanced Bioavailability of Atorvastatin Calcium from Stabilized Gastric Resident Formulation

  2011cites this paper
• Effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Korean subjects.

  2010cites this paper
• Trainable structure–activity relationship model for virtual screening of CYP3A4 inhibition

  2010cites this paper
• Toward a comprehensive molecular design framework for reduced hazard.

  2010cites this paper
• Sorption of statin pharmaceuticals to wastewater-treatment biosolids, terrestrial soils, and freshwater sediment.

  2010cites this paper
• Statins and neuroprotection

  2010cites this paper
• Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.

  2010cites this paper
• Quantitative correlation of physical and chemical properties with chemical structure: utility for prediction.

  2010cites this paper
• A System for LogD Screening of New Drug Candidates using a Water-Plug Injection Method and Automated Liquid Handler

  2009cites this paper
• Method for predicting the risk of drug–drug interactions involving inhibition of intestinal CYP3A4 and P-glycoprotein

  2009cites this paper
• Effects of acid and lactone forms of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on the induction of MDR1 expression and function in LS180 cells.

  2009cites this paper
• Improvement of the high-speed logD assay using an injection marker for the water plug aspiration/injection method.

  2009cites this paper
• Effects of Statins on the Pharmacokinetics of Midazolam in Healthy Volunteers

  2009cites this paper
• The Guinea Pig as a Preclinical Model for Demonstrating the Efficacy and Safety of Statins

  2008cites this paper
• High-speed solubility screening assay using ultra-performance liquid chromatography/mass spectrometry in drug discovery.

  2008cites this paper
• The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15

  2008cites this paper
• Comparative Analysis of Clinical and Non-Clinical Pharmacokinetic Interactions of Statins with Other Drugs

  2007cites this paper
• An interaction between statins and clopidogrel- A pharmacoepidemiology cohort study with survival time analysis

  2007cites this paper
• P-glycoprotein Has Differential Effects on the Disposition of Statin Acid and Lactone Forms in mdr1a/b Knockout and Wild-Type Mice

  2007influential citation
• Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin

  2007cites this paper
• A system for LogD screening of 96-well plates using a water-plug aspiration/injection method combined with high-performance liquid chromatography-mass spectrometry.

  2007cites this paper
• Comparison of three in vitro models expressing the membrane drug transporter OATP1B1

  2007cites this paper
• Prevention of stroke and dementia by statin therapy: experimental and clinical evidence of their pleiotropic effects.

  2007cites this paper
• Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and

  2007cites this paper
• Serotonin transporter protein in pulmonary hypertensive rats treated with atorvastatin.

  2007cites this paper
• Clinical Usefulness of a Database Predicting Drug-Drug Interactions Using Metabolic Information for Cytochrome P-450, as Evaluated from Dosage and Adverse Events of HMG-CoA Reductase Inhibitor Atorvastatin

  2006cites this paper
• A literature review of enzyme kinetic parameters for CYP3A4-mediated metabolic reactions of 113 drugs in human liver microsomes: structure-kinetics relationship assessment.

  2006cites this paper
• Complicating factors in safety testing of drug metabolites: kinetic differences between generated and preformed metabolites.

  2006cites this paper
• Statins Decrease Serotonin-Induced Contractions in Coronary Arteries of Swine in vitro

  2006cites this paper
• Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions.

  2006cites this paper
• A pharmacoepidemiology study of the interaction between atorvastatin and clopidogrel after percutaneous coronary intervention.

  2006cites this paper
• Drug interactions with lipid‐lowering drugs: Mechanisms and clinical relevance

  2006cites this paper
• Quantitative structure–activity relationships (QSARs) in CYP3A4 inhibitors: The importance of lipophilic character and hydrogen bonding

  2006cites this paper
• ERSPECTIVES IN CLINICAL HARMACOLOGY rug interactions with lipid-lowering rugs : Mechanisms and clinical relevance

  2006cites this paper
• SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid

  2006cites this paper
• Chronic Administration of Statins Alters Multiple Gene Expression Patterns in Mouse Cerebral Cortex

  2005influential citation
• Comparison of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) as inhibitors of cytochrome P450 2C8.

  2005cites this paper
• Strategies to improve oral drug bioavailability

  2005cites this paper
• DIFFERENTIAL INTERACTION OF 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE INHIBITORS WITH ABCB1, ABCC2, AND OATP1B1

  2005influential citation
• Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs

  2005cites this paper
• Effect of atorvastatin and fluvastatin on the metabolism of midazolam by cytochrome P450 in vitro *

  2005cites this paper
• Do the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases?

  2005cites this paper
• Existence of a clinically relevant interaction between clopidogrel and HMG-CoA reductase inhibitors? Re-evaluating the evidence.

  2005cites this paper
• Bile Salt Export Pump (BSEP/ABCB11) Can Transport a Nonbile Acid Substrate, Pravastatin

  2005cites this paper
• Application of ALOGPS 2.1 to predict log D distribution coefficient for Pfizer proprietary compounds.

  2004cites this paper
• Involvement of Multiple Transporters in the Efflux of 3-Hydroxy-3-methylglutaryl-CoA Reductase Inhibitors across the Blood-Brain Barrier

  2004cites this paper
• Compound lipophilicity for substrate binding to human P450s in drug metabolism.

  2004cites this paper
• Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4.

  2004cites this paper
• Induction of cytochromes P450.

  2004cites this paper
• Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors

  2004cites this paper
• DIFFERENTIAL INTERACTION OF HMG-CoA REDUCTASE INHIBITORS WITH ABCB1, ABCC2, AND OATP1B1

  2004influential citation
• Clinical Pharmacokinetics of Atorvastatin

  2003cites this paper
• Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization

  2003cites this paper
• Validation of a pre‐anaesthetic screening questionnaire

  2003cites this paper
• Interaction between Several Medicines and Statins

  2003cites this paper
• The effects of concurrent atorvastatin therapy on the pharmacokinetics of intravenous midazolam

  2003cites this paper
• Elimination of alfentanil delivered by infusion is not altered by the chronic administration of atorvastatin

  2003cites this paper
• CYP3A4 active site volume modification by mutagenesis of leucine 211.

  2002cites this paper
• Comparative beneficial effects of simvastatin and pravastatin on cardiac allograft rejection and survival.

  2002cites this paper
• Sex difference in inhibition of in vitro mexazolam metabolism by various 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors in rat liver microsomes.

  2002cites this paper
• Summary of information on human CYP enzymes: human P450 metabolism data

  2002cites this paper
• The influence of DMPK as an integrated partner in modern drug discovery.

  2002cites this paper